Opdivo Application Scope

Opdivo (nivolumab) is a PD-1 immune checkpoint inhibitor that enhances the immune system’s ability to fight cancer by blocking the PD-1 pathway, thereby promoting T-cell activation.

opdivo

Characteristics

Ingredients: Nivolumab

Properties: Human IgG4 monoclonal antibody targeting PD-1 receptors on T cells, enhancing immune response against tumors.
Packaging Specification:
Available in single-dose vials:
- 40 mg/4 mL
- 100 mg/10 mL

Storage: Store refrigerated at 2°C to 8°C (36°F to 46°F). Do not freeze. Protect from light.
Expiry Date: Refer to the specific vial’s labeling for expiration information.
Executive Standard: FDA-approved Biologics License Application (BLA) No. 125554.
Approval Number: BLA 125554
Date of Revision: Refer to the latest prescribing information for the most recent revision date.
Manufacturer: Bristol-Myers Squibb Company

Guidelines for the Use of Opdivo

Dosage and Administration:
- Dosage: Dosage varies based on cancer type, stage, and combination with other therapies.
  - Melanoma: 240 mg every 2 weeks or 480 mg every 4 weeks.
  - Non-Small Cell Lung Cancer (NSCLC): 240 mg every 2 weeks or 480 mg every 4 weeks.
  - In combination therapies, dosages are adjusted accordingly.
- Administration: Administered as an intravenous infusion over 30 minutes.

Adverse Reactions:
- Common (≥10%):
  - Fatigue, rash, musculoskeletal pain, pruritus, diarrhea, nausea, cough, dyspnea, constipation
  - decreased appetite, back pain, arthralgia, upper respiratory tract infection, pyrexia, headache, abdominal pain, vomiting.
- Serious:
  - Immune-mediated adverse reactions include pneumonitis, colitis, hepatitis, endocrinopathies, nephritis, and skin reactions.
Contraindications:
- None listed.
- However, caution is advised in patients with severe hypersensitivity to nivolumab or any of its components.
Precautions:
- Monitor for signs of immune-mediated adverse reactions.
- Use with caution in patients with pre-existing autoimmune conditions.
- Not recommended during pregnancy; may cause fetal harm.

Opdivo Interactions

Drug Interactions:
- No formal drug interaction studies have been conducted.
- However, immunosuppressive agents may diminish the efficacy of nivolumab.

Note:

If there is a new packaging for the drug, the new packaging shall prevail. The above information is sourced from DengYue Medicine.
It is only for internal discussion among medical staff and does not serve as a basis for medication. For specific medication guidelines, please consult the attending physician.